NCT06778902 (Dragon) is a Phase 2 clinical trial of azacytidine in DLBCL - Diffuse Large B Cell Lymphoma, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.

What drugs are being tested in NCT06778902?

Interventions in NCT06778902: azacytidine, R-GemOx.

What condition does NCT06778902 study?

NCT06778902 studies DLBCL - Diffuse Large B Cell Lymphoma.

Is NCT06778902 still recruiting?

NCT06778902 is currently not yet recruiting. Last updated 16 January 2025.

Last reviewed 2025-01-16 · How we verify

NCT06778902: Dragon

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZA Combined with R-GemOx for Elderly DLBCL Patients

Not yet recruiting Phase 2 Last updated 16 January 2025

What this trial tests

Phase 2 trial testing azacytidine in DLBCL - Diffuse Large B Cell Lymphoma in 80 participants. Not yet recruiting.

Timeline

1 February 2025

Primary endpoint
1 January 2028

1 January 2028

Quick facts

Lead sponsor	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 February 2025
Primary completion	1 January 2028
Estimated completion	1 January 2028
Sites	1 location across China

Drugs / interventions tested

azacytidine — full drug profile →
R-GemOx — full drug profile →

Conditions studied

DLBCL - Diffuse Large B Cell Lymphoma — all drugs for DLBCL - Diffuse Large B Cell Lymphoma →

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Who can join

Adults 60 to 90, any sex, with DLBCL - Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of AZA（azacytidine）combined with the R-GemOx (rituximab, gemcitabine and oxaliplatin) regimen as first-line treatment in elderly diffuse large B-cell lymphoma (DLBCL) patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of azacytidine

Trials testing the same drug.

NCT06694454 — Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for DLBCL - Diffuse Large B Cell Lymphoma

Currently open trials in the same condition.

NCT07288879 — DALY II Japan/MB-CART2019.1 for DLBCL · Phase 2 · recruiting
NCT07255963 — Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL · Phase 2 · recruiting
NCT06846463 — Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ · Phase 2 · recruiting
NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
NCT06891157 — Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes · Phase 2 · recruiting

Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

Trials by the same sponsor.

NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07467590 — Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Stud · Phase 2 · not yet recruiting
NCT07459192 — Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors · not yet recruiting
NCT07459179 — Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognit · not yet recruiting
NCT07459205 — Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06778902 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Last refreshed: 16 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06778902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing